Target intelligence / Profile preview

Glutamate ionotropic receptor kainate type subunit 1 (GluK1 (alternatively GRIK1))

Target
GluK1 (alternatively GRIK1)
Molecular classification
Receptor, Ion channel, Ligand-gated ion channel, Ionotropic glutamate receptor, Kainate receptor family (kainate subtype)
01

Overview

Glutamate ionotropic receptor kainate type subunit 1 (GluK1/GRIK1) is a protein subunit of kainate-type ionotropic glutamate receptors, acting as a ligand-gated cation channel predominantly in the brain. Activated by glutamate or kainic acid, these receptors contribute to fast excitatory neurotransmission and have critical roles in synaptic function and plasticity. GRIK1 is subject to RNA editing and alternative splicing, further diversifying its function and pharmacology. Abnormal activation or genetic variation in GRIK1 is implicated in seizure disorders (especially epilepsy), as well as wider neurological and psychiatric conditions. The receptor is actively studied for therapeutic modulation though few drugs directly target it in clinical practice

Other names
GluK1GRIK1Glutamate receptor, kainate 1Glutamate receptor, ionotropic kainate 1EAA3 (older literature)KA1, iGluR5 (less commonly used)
02

Mechanism of action

Agonists: Bind GluK1, open cation channel, depolarize neuronal membrane, increase excitatory currents Antagonists: Inhibit kainate receptor, reduce excitatory neurotransmission Positive allosteric modulators: Prolong activation, inhibit desensitization (e.g., concanavalin A, BPAM344) RNA editing/modulation: Alters channel permeability for calcium; potential implications in disease-modifying therapies

03

Biological functions

Signal transductionNeurotransmission (excitatory)Synaptic plasticityRegulation of neuronal circuitsModulation of excitatory/inhibitory balanceChannel for cations, especially sodium and (modulated) calcium
04

Disease associations

Epilepsy (temporal lobe epilepsy, juvenile absence epilepsy)Neurodegenerative diseasePsychiatric disorders (schizophrenia, depression, autism, anxiety)Seizure susceptibility and related syndromes
05

Safety considerations

Excessive activation can induce seizures (kainic acid used as experimental proconvulsant)Excitotoxicity risk in CNS if dysregulated.Broad CNS expression means off-target effects are plausible for drugs targeting GluK1.Kainate antagonists not yet fully validated as epilepsy therapeutics; potential efficacy but risks of altering normal CNS function
06

Interacting drugs

Kainic acid (agonist, experimental inducer of seizures in animal models)

4 more in the full profile.

07

Biomarkers

GRIK1 expression or variant (e.g., His289Tyr) as a biomarker for seizure susceptibility in animal modelsElevated GluK1 protein levels or altered distribution possibly relevant to temporal lobe epilepsyNo established clinical biomarkers for patient selection; emerging preclinical research.

Beyond the preview

Go deeper on Glutamate ionotropic receptor kainate type subunit 1 (GluK1 (alternatively GRIK1)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Glutamate ionotropic receptor kainate type subunit 1 (GluK1 (alternatively GRIK1)).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call